Casdin Capital LLC Grows Stake in Denali Therapeutics Inc. $DNLI

Casdin Capital LLC boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 106.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,840,000 shares of the company’s stock after buying an additional 950,000 shares during the period. Denali Therapeutics accounts for approximately 1.9% of Casdin Capital LLC’s portfolio, making the stock its 12th biggest holding. Casdin Capital LLC owned about 1.25% of Denali Therapeutics worth $30,378,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $26,000. Johnson Financial Group Inc. acquired a new position in Denali Therapeutics in the third quarter valued at $29,000. State of Wyoming acquired a new position in Denali Therapeutics in the second quarter valued at $29,000. Aster Capital Management DIFC Ltd acquired a new position in Denali Therapeutics in the fourth quarter valued at $57,000. Finally, Quarry LP acquired a new position in Denali Therapeutics in the third quarter valued at $64,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 7.1%

Denali Therapeutics stock opened at $23.49 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. The stock has a market cap of $3.73 billion, a PE ratio of -8.16 and a beta of 1.03. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $24.21. The firm’s 50-day simple moving average is $19.94 and its 200 day simple moving average is $19.52.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the previous year, the firm earned ($0.78) EPS. Research analysts predict that Denali Therapeutics Inc. will post -2.77 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on DNLI shares. Jefferies Financial Group reissued a “buy” rating and set a $40.00 price target on shares of Denali Therapeutics in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Monday, April 20th. Leerink Partners decreased their target price on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Deutsche Bank Aktiengesellschaft set a $31.00 target price on Denali Therapeutics in a report on Friday, May 22nd. Finally, HC Wainwright lifted their target price on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.25.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.